PL2231689T3 - Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych - Google Patents

Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych

Info

Publication number
PL2231689T3
PL2231689T3 PL09702842T PL09702842T PL2231689T3 PL 2231689 T3 PL2231689 T3 PL 2231689T3 PL 09702842 T PL09702842 T PL 09702842T PL 09702842 T PL09702842 T PL 09702842T PL 2231689 T3 PL2231689 T3 PL 2231689T3
Authority
PL
Poland
Prior art keywords
deazapurine nucleosides
novel cytostatic
cytostatic
novel
deazapurine
Prior art date
Application number
PL09702842T
Other languages
English (en)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic filed Critical Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic
Publication of PL2231689T3 publication Critical patent/PL2231689T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL09702842T 2008-01-18 2009-01-15 Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych PL2231689T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
PL2231689T3 true PL2231689T3 (pl) 2017-01-31

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
PL09702842T PL2231689T3 (pl) 2008-01-18 2009-01-15 Nowe 7-deazapurynowe nukleozydy o właściwościach cytostatycznych
PL16174985T PL3133080T3 (pl) 2008-01-18 2009-01-15 Nowe cytostatyczne nukleozydy 7-deazapurynowe

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL16174985T PL3133080T3 (pl) 2008-01-18 2009-01-15 Nowe cytostatyczne nukleozydy 7-deazapurynowe

Country Status (18)

Country Link
US (1) US8093226B2 (pl)
EP (2) EP3133080B1 (pl)
JP (2) JP5485172B2 (pl)
CN (1) CN101977923B (pl)
AU (1) AU2009204568B2 (pl)
CA (1) CA2711384C (pl)
CY (2) CY1118104T1 (pl)
DK (2) DK2231689T3 (pl)
ES (2) ES2693551T3 (pl)
HR (2) HRP20161344T1 (pl)
HU (2) HUE030767T2 (pl)
LT (2) LT3133080T (pl)
NZ (1) NZ586610A (pl)
PL (2) PL2231689T3 (pl)
PT (2) PT3133080T (pl)
SI (2) SI2231689T1 (pl)
TR (1) TR201815961T4 (pl)
WO (1) WO2009089804A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CN102459300B (zh) * 2009-04-22 2014-12-10 捷克有机化学和生物化学研究院 用于治疗用途的新的7-脱氮嘌呤核苷
SG176111A1 (en) * 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
JP5775070B2 (ja) * 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
CN103221048A (zh) * 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
US20220152072A1 (en) * 2019-04-05 2022-05-19 Prelude Therapeutics, Incorporated Selective Inhibitors Of Protein Arginine Methyltransferase 5 (PRMT5)
MX2021015772A (es) * 2019-06-18 2022-01-31 Taiho Pharmaceutical Co Ltd Compuesto de carbonato novedoso que tiene esqueleto de pirrolopirimidina o sal farmaceuticamente aceptable del mismo.
WO2021164848A1 (en) * 2020-02-17 2021-08-26 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (pl) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
CN1863813B (zh) * 2003-08-27 2011-03-30 生物区科学管理控股有限公司 作为治疗剂的三环核苷或核苷酸
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CA2584367A1 (en) 2004-10-21 2006-06-22 Merck & Co., Inc. Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection
AR056327A1 (es) * 2005-04-25 2007-10-03 Genelabs Tech Inc Compuestos de nucleosidos para el tratamiento de infecciones virales

Also Published As

Publication number Publication date
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
CN101977923B (zh) 2014-10-08
PT3133080T (pt) 2018-11-16
CA2711384A1 (en) 2009-07-23
AU2009204568A1 (en) 2009-07-23
DK2231689T3 (en) 2016-09-19
AU2009204568B2 (en) 2013-10-03
ES2598503T3 (es) 2017-01-27
LT2231689T (lt) 2016-10-25
JP2011509949A (ja) 2011-03-31
SI2231689T1 (sl) 2016-11-30
JP5485172B2 (ja) 2014-05-07
EP2231689A1 (en) 2010-09-29
EP3133080A1 (en) 2017-02-22
SI3133080T1 (sl) 2018-12-31
EP3133080B1 (en) 2018-08-01
PT2231689T (pt) 2016-10-07
US8093226B2 (en) 2012-01-10
US20090203637A1 (en) 2009-08-13
TR201815961T4 (tr) 2018-11-21
CY1118104T1 (el) 2017-06-28
CA2711384C (en) 2016-07-26
EP2231689B1 (en) 2016-07-20
HUE041598T2 (hu) 2019-05-28
CN101977923A (zh) 2011-02-16
NZ586610A (en) 2012-08-31
PL3133080T3 (pl) 2018-12-31
HRP20161344T1 (hr) 2016-11-18
JP2014058567A (ja) 2014-04-03
CY1121364T1 (el) 2020-05-29
HUE030767T2 (en) 2017-05-29
ES2693551T3 (es) 2018-12-12
WO2009089804A1 (en) 2009-07-23
LT3133080T (lt) 2018-11-12

Similar Documents

Publication Publication Date Title
LT3133080T (lt) Naujieji citostatiniai 7-deazapurino nukleozidai
ZA201101104B (en) Novel adenine derivatives
ZA201008829B (en) Nucleoside cyclicphosphates
SI2421879T1 (sl) Novi 7-deazapurinski nukleozidi za terapevtske uporabe
IL213698A0 (en) Nucleoside phosphoramidates
ZA201104638B (en) Nucleoside analogs
IL200831A0 (en) Novel adenine compounds
IL205625A0 (en) Antiviral nucleoside compounds
IL213701A0 (en) Synthesis of purine nucleosides
AP2009005073A0 (en) Antiviral compounds
IL210207A0 (en) Compounds having antiviral properties
IL213167A0 (en) Purine compounds
ZA201006647B (en) Antiviral therapy
GB0803707D0 (en) Antiviral agent
GB0723609D0 (en) Antiviral
HK1149016A (en) Novel cytostatic 7-deazapurine nucleosides
IL207312A0 (en) Cytostatic composition
GB0816600D0 (en) Antiviral compounds
IL192335A0 (en) Antiviral compounds
GB0819528D0 (en) Antiviral compounds
GB0704852D0 (en) Furanose derivatives
GB0717955D0 (en) Preparation of modified nucleosides
GB0803654D0 (en) Buster brackets (KA-2 + KA-9)
GB0819857D0 (en) Antiviral therapy